Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Age is a strong risk factor for cardiovascular disease. Accordingly, most cardiovascular risk prediction models have included age as an independent risk factor. There is much evidence that effective management of cardiovascular risk factors improves clinical outcomes even in older adults. However, there are concerns that intensive treatment for older adults increases the risk of adverse events. For hypertensive patients, intensive blood pressure reduction with combination therapy increases the risk of syncope, acute kidney injury, and falls. Intensive glucose-lowering therapy among older patients with diabetes increases the risk of hypoglycemia or cognitive impairment. These findings suggest that a balanced approach for older adults is required to increase the benefits and decrease the risk of side effects. In contrast to older people, the estimated 10-year cardiovascular risk in young and healthy individuals is low. However, the lifetime cardiovascular risk in these patients is actually high. The 2021 European Society of Cardiology guideline on cardiovascular disease prevention in clinical practice has been published. It proposed a different risk stratification and recommendation for treatment according to age group, based on the concept of avoiding undertreatment in young people and overtreatment in older persons. Although the guideline recommends age-dependent risk stratification, risk categories should not be applied to the mandatory initiation of drug treatment. In all age groups, other factors such as lifetime cardiovascular risk, treatment benefit and harm, comorbidities, frailty, and patient preferences should be considered when managing patients for primary prevention.
Abstract
Age is a strong risk factor for cardiovascular disease. Accordingly, most cardiovascular risk prediction models have included age as an independent risk factor. There is much evidence that effective management of cardiovascular risk factors improves clinical outcomes even in older adults. However, there are concerns that intensive treatment for older adults increases the risk of adverse events. For hypertensive patients, intensive blood pressure reduction with combination therapy increases the risk of syncope, acute kidney injury, and falls. Intensive glucose-lowering therapy among older patients with diabetes increases the risk of hypoglycemia or cognitive impairment. These findings suggest that a balanced approach for older adults is required to increase the benefits and decrease the risk of side effects. In contrast to older people, the estimated 10-year cardiovascular risk in young and healthy individuals is low. However, the lifetime cardiovascular risk in these patients is actually high. The 2021 European Society of Cardiology guideline on cardiovascular disease prevention in clinical practice has been published. It proposed a different risk stratification and recommendation for treatment according to age group, based on the concept of avoiding undertreatment in young people and overtreatment in older persons. Although the guideline recommends age-dependent risk stratification, risk categories should not be applied to the mandatory initiation of drug treatment. In all age groups, other factors such as lifetime cardiovascular risk, treatment benefit and harm, comorbidities, frailty, and patient preferences should be considered when managing patients for primary prevention.
참고문헌 (33)
- Tsao CW, "Heart disease and stroke statistics-2022 update : a report from the American Heart Association", Circulation, 145, pp.e153~e639 (2022)
- Spencer-Bonilla G, "Statin use in older adults with stable atherosclerotic cardiovascular disease", J Am Geriatr Soc, 69, pp.979~985 (2021)
- Grundy SM, "2018 AHA", ACC, AAPA, pp.ABC, ACPM[DOI]
- Berkelmans GF, "Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with type 2 diabetes mellitus", Eur Heart J, 40, pp.2899~2906 (2019)
- Emberson J, "Evaluating the impact of population and high-risk strategies for the primary prevention of cardiovascular disease", Eur Heart J, 25, pp.484~491 (2004)
- Siontis GC, "Comparisons of established risk prediction models for cardiovascular disease: systematic review", BMJ, 344, pp.e3318~ (2012)
- Goff DC Jr, "2013 ACC", AHA guideline on the assessment of cardiovascular risk : a report of the American College of Cardiology, Circulation, pp.2014, 129[DOI]
- Liu J, "Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study", JAMA, 291, pp.2591~2599 (2004)
- Jung KJ, "The ACC", AHA 2013 pooled cohort equations compared to a Korean Risk Prediction Model for atherosclerotic cardiovascular disease, 2015, pp.242, 367~375
- Kavousi M, "Comparison of application of the ACC", AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort, 2014, pp.311, 1416~1423
- Systematic review of cardiovascular disease risk assessment tools, "Matheny M", Agency for Healthcare Research and Quality (US), ~ (2011)
- Rana JS, "Accuracy of the atherosclerotic cardiovascular risk equation in a large contemporary, multiethnic population", J Am Coll Cardiol, 67, pp.2118~2130 (2016)
- DeFilippis AP, "Risk score overestimation : the impact of individual cardiovascular risk factors and preventive therapies on the performance of the American Heart Association-American College of Cardiology-Atherosclerotic Cardiovascular Disease risk score in a modern multi-ethnic cohort", Eur Heart J, 38, pp.598~608 (2017)
- Rapsomaniki E, "Blood pressure and incidence of twelve cardiovascular diseases : lifetime risks, healthy life-years lost, and age-specific associations in 1·25 million people", Lancet, 383, pp.1899~1911 (2014)
- Nanna MG, "The accuracy of cardiovascular pooled cohort risk estimates in U. S. older adults", J Gen Intern Med, 35, pp.1701~1708 (2020)
- Berry JD, "Lifetime risks of cardiovascular disease", N Engl J Med, 366, pp.321~329 (2012)
- Visseren FL, "2021 ESC guidelines on cardiovascular disease prevention in clinical practice", Eur Heart J, 42, pp.3227~3337 (2021)
- Jaspers NE, "Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people", Eur Heart J, 41, pp.1190~1199 (2020)
- Lloyd-Jones DM, "Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age", Circulation, 113, pp.791~798 (2006)
- Pedretti RF, "How to optimize the adherence to a guideline-directed medical therapy in the secondary prevention of cardiovascular diseases : a clinical consensus statement from the European Association of Preventive Cardiology", Eur J Prev Cardiol, 30, pp.149~166 (2023)
- Conroy RM, "Estimation of ten-year risk of fatal cardiovascular disease in Europe : the SCORE project", Eur Heart J, 24, pp.987~1003 (2003)
- SCORE2 Working Group, "SCORE2 risk prediction algorithms : new models to estimate 10-year risk of cardiovascular disease in Europe", Eur Heart J, 42, pp.2439~2454 (2021)
- SCORE2-OP Working Group, "SCORE2-OP risk prediction algorithms : estimating incident cardiovascular event risk in older persons in four geographical risk regions", Eur Heart J, 42, pp.2455~2467 (2021)
- US Preventive Services Task Force, "Statin use for the primary prevention of cardiovascular disease in adults : US Preventive Services Task Force recommendation statement", JAMA, 328, pp.746~753 (2022)
- Cholesterol Treatment Trialists’ Collaboration, "Efficacy and safety of statin therapy in older people : a meta-analysis of individual participant data from 28 randomised controlled trials", Lancet, 393, pp.407~415 (2019)
- Ouchi Y, "Ezetimibe Lipid-Lowering Trial on Prevention of Atherosclerotic Cardiovascular Disease in 75 or Older(EWTOPIA 75) : a randomized, controlled trial", Circulation, 140, pp.992~1003 (2019)
- US Preventive Services Task Force, "Aspirin use to prevent cardiovascular disease : US Preventive Services Task Force recommendation statement", JAMA, 327, pp.1577~1584 (2022)
- ElSayed NA, "13. Older adults : standards of care in diabetes-2023", Diabetes Care, 46, pp.S216~S229 (2023)
- Kontis V, "Future life expectancy in 35 industrialised countries : projections with a Bayesian model ensemble", Lancet, 389, pp.1323~1335 (2017)
- Mega JL, "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy : an analysis of primary and secondary prevention trials", Lancet, 385, pp.2264~2271 (2015)
- Aragam KG, "Limitations of contemporary guidelines for managing patients at high genetic risk of coronary artery disease", J Am Coll Cardiol, 75, pp.2769~2780 (2020)
- Sánchez-Cabo F, "Machine learning improves cardiovascular risk definition for young, asymptomatic individuals", J Am Coll Cardiol, 76, pp.1674~1685 (2020)
- Krittanawong C, "Artificial intelligence in precision cardiovascular medicine", J Am Coll Cardiol, 69, pp.2657~2664 (2017)